3 Global Generics and Specialty Company, Domestic Brands Leader and Contract Formulations Maker Stocks With a Strong Future Roadmap: Lupin, Mankind Pharma and Innova Captab

Global generic, home brand and contract stocks bring together companies with a visible plan for the years ahead. Lupin, Mankind Pharma and Innova Captab cover a global generics and specialty company, a domestic brands leader and a contract formulations maker.

This list covers three global generic, home brand and contract stocks with complete current figures: Lupin, Mankind Pharma and Innova Captab. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Global Generic, Home Brand and Contract Stocks?

Global generic, home brand and contract stocks are listed drug makers that sell generics overseas, popular brands in India and formulations made for other companies. Their earnings depend on launches, prescriptions, approvals and plant quality.

Global Generic, Home Brand and Contract Stocks at a Glance

On valuation, Lupin trades at a P/E below the industry P/E, while Mankind Pharma and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing global generic, home brand and contract stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in global generic, home brand and contract stocks can use the coming numbers to test whether growth is holding.

Why Do Global Generic, Home Brand and Contract Stocks Have a Strong Roadmap in India?

Global generic, home brand and contract stocks have a strong roadmap in India because a wide product pipeline, strong doctor reach and outsourced manufacturing keep widening the revenue base.

• Product pipeline. New launches in regulated markets add revenue.
• Doctor reach. Large field teams push brands across cities.
• Contract work. Other drug companies outsource formulations.

Why Lupin Features Among These Global Generic, Home Brand and Contract Stocks

Among the global generic, home brand and contract stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Why Mankind Pharma Features Among These Global Generic, Home Brand and Contract Stocks

Among the Lupin and Mankind brand shares on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.

Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%.

In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.

Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What to watch: Watch the market share in chronic therapies and the integration of acquired brands.

Why Innova Captab Features Among These Global Generic, Home Brand and Contract Stocks

Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Lupin vs Mankind Pharma vs Innova Captab on Key Financials

The table below sets the three global generic, home brand and contract stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with global generic, home brand and contract stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several prescription brand and formulation maker stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Global Generic, Home Brand and Contract Stocks

Every theme carries risks that deserve a check before any decision. For these global generic, home brand and contract stocks, the main points are: Long-term Lupin and Mankind brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Price pressure. Generic prices abroad can fall.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter global generic, home brand and contract stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Global Generic, Home Brand and Contract Stocks

Global generic, home brand and contract stocks suit investors who prefer to study business strength before price moves. Lupin, Mankind Pharma and Innova Captab each have a clear plan to grow. Based on the 23 October 2026 close, Lupin trades at Rs 1,928.9, Mankind Pharma at Rs 2,212.6 and Innova Captab at Rs 987.3. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these global generic, home brand and contract stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track global generic, home brand and contract stocks, set price alerts and get research-backed stock ideas.

What are global generic, home brand and contract stocks?

Ans. Global generic, home brand and contract stocks are listed drug makers that sell generics overseas, popular brands in India and formulations made for other companies. Their earnings depend on launches, prescriptions, approvals and plant quality. This list looks at three of them, Lupin, Mankind Pharma and Innova Captab, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.

Which global generic, home brand and contract stocks are covered in this list?

Ans. This list covers Lupin, Mankind Pharma and Innova Captab. Based on the 23 October 2026 close, Lupin traded at Rs 1,928.9, Mankind Pharma at Rs 2,212.6 and Innova Captab at Rs 987.3. Their return on equity ranges from 11.7% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.0% to 19.5%.

Why do global generic, home brand and contract stocks have a strong future roadmap in India?

Ans. Global generic, home brand and contract stocks have a strong roadmap in India because a wide product pipeline, strong doctor reach and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Product pipeline. New launches in regulated markets add revenue. Doctor reach. Large field teams push brands across cities. Contract work. Other drug companies outsource formulations. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

How has Mankind Pharma performed financially?

Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What risks should investors check before buying global generic, home brand and contract stocks?

Ans. Investors should check a few risks before buying global generic, home brand and contract stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of global generic, home brand and contract stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.